Clinical Trial Update: Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating chemotherapy followed by ESO-1 lymphocytes and aldesleukin in metastatic cancer was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• ESO-1 lymphocytes (ESO-1 lymphocytes)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Metastatic Renal Cell Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-06-27